CompletedPhase 1

A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

A Parallel-group, Phase 1, Open-label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Renal Impairment Compared With Healthy Participants

Lead sponsor

Eli Lilly and Company

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

Actual enrollment

Study population

Healthy volunteers, Renal impairment

Eligibility highlights

•BMI 19-40•HbA1c 5-11.5%•eGFR ≥90•Healthy volunteers

Primary endpoints

•AUC•PK: Maximum observed concentration (Cmax) of LY3437943

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05611957

Org study ID18529

Secondary IDJ1I-MC-GZBLEli Lilly and Company

Timeline

Milestones

Study first posted2022-11-10actual

Study start2022-11-16actual

Primary completion2023-09-05actual

Study completion2023-09-05actual

Last update posted2023-10-02actual

Assets

Investigational agents

Retatrutide

Who this study enrolls

Healthy volunteersRenal impairment

Who can enroll

Minimum age18 Years

Maximum age85 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

Normal Participants:

•Healthy male and female participants as determined by physical examination

•Participants with normal renal function assessed by estimated glomerular filtration rate (eGFR) ≥ 90 milliliter per minute (mL/min).

•Body mass index (BMI) ≥ 19.0 and ≤ 40.0 kilograms per meter squared (kg/m²)

•Male participants who agree to use contraception and female participants of child bearing potential must agree to use contraceptive methods and women not of child bearing potential can participate.

Participants with Renal Impairment:

•Have acceptable blood pressure (BP) and pulse rate, as determined by the investigator

•Participants with type 2 diabetes must have a glycated hemoglobin (HbA1c) ≥ 5.0% and ≤ 11.5%

•Are males or females with severe renal impairment as determined by a stable eGFR <30 mL/min, not requiring hemodialysis OR

•Are males or females with end-stage renal disease (have received hemodialysis for at least 3 months)

Exclusion criteria

•Have known allergies to LY3437943 or related compounds

•Have a current, functioning organ transplant. Nonfunctional renal allografts may be allowed

•Have any abnormality in the 12-lead electrocardiogram (ECG)

•Are women with a positive pregnancy test or women who are lactating

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943

Time frame:Predose up to 31 days postdose

AUC₀-∞

concentration, descriptive

Primary/protocol endpoint

PK: Maximum observed concentration (Cmax) of LY3437943

Time frame:Predose up to 31 days postdose

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.